ImmTune Therapies is one of the top 3 finalists for Merck’s emerging biotechs grant programme, aimed at supporting young biotechs with Merck’s expertise.

updates
Written By Bakul Gupta

ImmTune Therapies is one of the top 3 finalists for Merck’s emerging biotechs grant programme, aimed at supporting young biotechs with Merck’s expertise, and providing access to Merck’s research facilities.

Bakul Gupta
Previous

ImmTune wins the inaugural Future Innovator prize awarded by Astella pharma and we are the pioneer group
Next

Our CEO and Co-founder has been named as one of the top movers and shakers in biobusiness in 2020.